The analyst rating for JD HEALTH (06618.HK) and ALI HEALTH (00241.HK) is based on their strong revenue growth, particularly in pharmaceutical sales, which increased by 20-30% and significantly outperformed the national market's overall growth of only 2%. This growth reflects the continuous market share gain by online platforms from hospital channels. CLSA maintained a rating of Outperform for JD HEALTH and a Buy/Hold rating for ALI HEALTH, while also raising their target prices, indicating a potential upside of approximately 6.5%. However, HSBC Global Research noted that ALI HEALTH's current valuation has largely accounted for recent AI developments, suggesting limited upside potential for that stock.
